Vedanta’s long-awaited demerger culminated with the listing of four newly spun-off businesses, triggering a sharp market re-rating and unlo...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...

OpenAI did not disclose the size or terms of the offering, and said a timeline has not yet been determined. "It may be a while because ther...

India is attracting foreign debt capital by removing taxes and easing borrowing rules. This move is expected to inject significant liquidit...

AI giant OpenAI has confidentially filed for a US initial public offering. This move follows rival Anthropic's similar filing. Investors ar...

OpenAI has launched Lockdown Mode to combat prompt injection attacks, a security feature designed for users handling sensitive data. This m...

With inflation on the rise, Indian shoppers are favoring compact product packaging. This shift not only reflects changing consumer habits b...

The Indian textile and apparel sector has had a stressful year. The US tariffs disrupted orders to the sector’s largest market, squeezed ma...

Happy Wednesday! Policybazaar’s Yashish Dahiya has warned that proposed commission caps could disrupt the insurance distribution industry. ...

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...

A growing number of couples are choosing to delay parenthood in pursuit of career milestones, financial stability, and personal goals. But ...

Markets closed lower amid geopolitical tensions, rupee weakness, and rising inflation. Upcoming week will be sensitive to US-Iran conflict ...